Donald G Phinney

Donald G Phinney, Ph.D.

Professor

Department: SR-MM-PHINNEY LAB
Business Phone: (561) 228-2214
Business Email: dphinney@ufl.edu

About Donald G Phinney

Dr. Phinney received his B.A. in Chemistry and Mathematics from the University of Vermont and a Ph.D. in Biochemistry from Temple University School of Medicine in Philadelphia. He then completed his post-doctoral studies at the Fox Chase Cancer Center where he was awarded an American Cancer Society Fellowship to examine the transcriptional regulation of the JunB oncogene. Dr. Phinney then spent nine years at Tulane University Health Sciences Center where he advanced through the ranks to Professor of Immunology and Microbiology and Associate Director of Research for the Center for Gene Therapy. He joined Scripps Florida in 2009 and is currently a Professor in the Department of Molecular Medicine.

Related Links:
Additional Positions:
Chairman, Molecular Therapeutics
2015 – 2017 · Scripps Research
Professor, Molecular Therapeutics
2009 – 2017 · Scripps Research
Director, Good Manufacturing Procedure Facility
2008 – 2009 · Tulane University
Associate Director of Research, Center for Gene Therapy
2007 – 2009 · Tulane University
Associate Professor with Tenure, Health Sciences Center
2000 – 2007 · Tulane University
Assistant Professor, Health Sciences Center
2000 – 2002 · Tulane University
Assistant Professor, Center for Gene Therapy
1996 – 2000 · Tulane University
Assistant Professor, Department of Pathology and Laboratory Medicine
1996 – 2000 · Medical College of Pennsylvania and Hahnemann University
Instructor, Institute for Molecular Medicine
1995 – 1996 · Thomas Jefferson University
American Cancer Society Fellow
1992 – 1995 · Fox Chase Cancer Center
Postdoctoral Associate
1990 – 1992 · Fox Chase Cancer Center

Accomplishments

Member
2011-2022 · MSC Committee, International Society of Cell Therapy (ISCT)
Lead Reviewer Award
2006 · Stem Cells
Member
2002-2005 · Planning Committee, International Society of Stem Cell Research
Member
2002-2003 · Scientific Advisory Board, StemSource Inc.
Fellow
1992-1994 · American Cancer Society
Nominee for Outstanding Academic Sophomore
1982 · UVM College of Arts and Sciences
Scholarship Award
1980-1984 · Atkinson Academy
Honors in Chemistry
1979 · St. Paul’s Academy, Advanced Study Program

Research Profile

The Phinney lab combines basic and translational research and drug discovery to deliver highly efficacious cell-based and drug-based therapies for the treatment of skeletal-related pathologies and cancer. Currently the lab is pursuing several different areas of investigation to achieve these goals. One area of focus is directed at enhancing the potency and improving the efficacy of mesenchymal stem cell (MSC)-based therapies, which are widely used in regenerative medicine for the treatment of ischemic and immune-related diseases. These efforts have culminated in the development of a Clinical Indications Prediction (CLIP) Scale that may be used to develop MSC-based therapies tailored to specific disease indications. Ongoing work is directed at validating the CLIP scale and expanding its range of applications. Another area of focus is directed at understanding the molecular mechanism that drive skeletal pathology in response to diet-induced obesity, mechanical unloading (disuse), and chronological aging using mouse models. In these studies, emphasis is on evaluating how these conditions impact the frequency and function of nice resident skeletal stem cells in bone marrow and developing therapeutics to preserve bone integrity. Lastly, the laboratory is also pursuing development of small molecule therapeutics to augment the efficacy and reduce the toxicity of existing chemotherapeutics and immuno-therapies for treating breast cancer.

Open Researcher and Contributor ID (ORCID)

0000-0002-8688-2619

Publications

2024
Alexander Friedenstein, Mesenchymal Stem Cells, Shifting Paradigms and Euphemisms
Bioengineering. 11(6) [DOI] 10.3390/bioengineering11060534.
2024
Comparative transcriptome analysis of bone marrow resident versus culture-expanded mouse mesenchymal stem/stromal cells
Cytotherapy. 26(5):498-505 [DOI] 10.1016/j.jcyt.2024.01.008. [PMID] 38372680.
2023
Graph neural networks for the identification of novel inhibitors of a small RNA
SLAS Discovery. 28(8):402-409 [DOI] 10.1016/j.slasd.2023.10.002.
2023
Mesenchymal stem/stromal cells from a transplanted, asymptomatic patient with Fanconi anemia exhibit an aging-like phenotype and dysregulated expression of genes implicated in hematopoiesis and myelodysplasia
Cytotherapy. 25(4):362-368 [DOI] 10.1016/j.jcyt.2022.11.003. [PMID] 36481320.
2023
Revisiting the Mesenchymal “Stem vs. Stromal” Cell Dichotomy and Its Implications for Development of Improved Potency Metrics
Stem Cells. 41(5):444-452 [DOI] 10.1093/stmcls/sxad019. [PMID] 36891977.
2023
Transcriptional Targets of TWIST1 in Human Mesenchymal Stem/Stromal Cells Mechanistically Link Stem/Progenitor and Paracrine Functions
Stem Cells. 41(12):1185-1200 [DOI] 10.1093/stmcls/sxad070. [PMID] 37665974.
2023
TWIST1 and TSG6 are coordinately regulated and function as potency biomarkers in human MSCs
Science Advances. 9(45) [DOI] 10.1126/sciadv.adi2387. [PMID] 37948519.
2022
An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells Committee editorial on overcoming limitations in clinical trials of mesenchymal stromal cell therapy for coronavirus disease-19: time for a global registry
Cytotherapy. 24(11):1071-1073 [DOI] 10.1016/j.jcyt.2022.07.010. [PMID] 36028438.
2022
Letter from the Editor.
Cytotherapy. 24(1) [DOI] 10.1016/j.jcyt.2021.11.001. [PMID] 34980363.
2022
Pharmacological Inhibition of Inositol Hexakisphosphate Kinase 1 Protects Mice against Obesity-Induced Bone Loss
Biology. 11(9) [DOI] 10.3390/biology11091257. [PMID] 36138736.
2021
Author Correction: Transcriptional responses of skeletal stem/progenitor cells to hindlimb unloading and recovery correlate with localized but not systemic multi-systems impacts
npj Microgravity. 7(1) [DOI] 10.1038/s41526-021-00184-2. [PMID] 34911973.
2021
Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling
Nature Chemical Biology. 17(3):307-316 [DOI] 10.1038/s41589-020-00719-w. [PMID] 33510451.
2021
Consensus International Council for Commonality in Blood Banking Automation-International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells.
Cytotherapy. 23(12):1060-1063 [DOI] 10.1016/j.jcyt.2021.04.009. [PMID] 34116944.
2021
ISCT special issue introduction.
Cytotherapy. 23(5) [DOI] 10.1016/j.jcyt.2021.03.004. [PMID] 33934806.
2021
Mesenchymal Stem Cell (MSC)-Derived Extracellular Vesicles Protect from Neonatal Stroke by Interacting with Microglial Cells.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 18(3):1939-1952 [DOI] 10.1007/s13311-021-01076-9. [PMID] 34235636.
2021
Mesenchymal stem cell-derived extracellular vesicles reduce senescence and extend health span in mouse models of aging.
Aging cell. 20(4) [DOI] 10.1111/acel.13337. [PMID] 33728821.
2021
Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition.
Cytotherapy. 23(5):368-372 [DOI] 10.1016/j.jcyt.2020.11.007. [PMID] 33714704.
2021
Transcriptional responses of skeletal stem/progenitor cells to hindlimb unloading and recovery correlate with localized but not systemic multi-systems impacts
npj Microgravity. 7(1) [DOI] 10.1038/s41526-021-00178-0. [PMID] 34836964.
2020
Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential.
Cytotherapy. 22(11):602-605 [DOI] 10.1016/j.jcyt.2020.04.089. [PMID] 32933835.
2020
Dear Speakers and Abstract Presenters of ISCT 2020 Paris Virtual.
Cytotherapy. 22(5S) [DOI] 10.1016/j.jcyt.2020.04.097. [PMID] 32456953.
2020
Improving mesenchymal stem/stromal cell potency and survival: Proceedings from the International Society of Cell Therapy (ISCT) MSC preconference held in May 2018, Palais des Congrès de Montréal, Organized by the ISCT MSC Scientific Committee.
Cytotherapy. 22(3):123-126 [DOI] 10.1016/j.jcyt.2020.01.004. [PMID] 32067856.
2020
International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19.
Cytotherapy. 22(9):482-485 [DOI] 10.1016/j.jcyt.2020.05.002. [PMID] 32425691.
2020
Introduction of new commissioning editor.
Cytotherapy. 22(11) [DOI] 10.1016/j.jcyt.2020.09.001. [PMID] 33004266.
2020
ISCT Talking with Giants Trilogy.
Cytotherapy. 22(4):173-179 [DOI] 10.1016/j.jcyt.2020.03.001. [PMID] 32305112.
2020
Open access versus accessibility: Evaluating Plan S.
Cytotherapy. 22(8) [DOI] 10.1016/j.jcyt.2020.03.435. [PMID] 32527644.
2019
Forward for two review articles authored by ISCT’s North American Legal & Regulatory Affairs Committee on the regulatory framework for cellular & gene therapy product approval in the U.S. and Canada.
Cytotherapy. 21(7) [DOI] 10.1016/j.jcyt.2019.06.004. [PMID] 31307697.
2019
Manufacturing mesenchymal stromal cells for clinical applications: A survey of Good Manufacturing Practices at U.S. academic centers.
Cytotherapy. 21(7):782-792 [DOI] 10.1016/j.jcyt.2019.04.003. [PMID] 31182333.
2019
Mesenchymal stem cell perspective: cell biology to clinical progress
npj Regenerative Medicine. 4(1) [DOI] 10.1038/s41536-019-0083-6. [PMID] 31815001.
2019
Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature.
Cytotherapy. 21(10):1019-1024 [DOI] 10.1016/j.jcyt.2019.08.002. [PMID] 31526643.
2019
Talking with Giants Introduction.
Cytotherapy. 21(4) [DOI] 10.1016/j.jcyt.2019.03.310. [PMID] 31029248.
2018
Basal p53 expression is indispensable for mesenchymal stem cell integrity
Cell Death & Differentiation. 25(4):679-692 [DOI] 10.1038/s41418-017-0004-4. [PMID] 29311623.
2018
Mesenchymal Stem Cells: The Moniker Fits the Science
Stem Cells. 36(1):7-10 [DOI] 10.1002/stem.2713.
2018
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.
Journal of extracellular vesicles. 7(1) [DOI] 10.1080/20013078.2018.1535750. [PMID] 30637094.
2017
Advancing mesenchymal stem/stromal cells-based therapies for neurologic disease.
Neural regeneration research. 12(1):60-61 [DOI] 10.4103/1673-5374.198978. [PMID] 28250743.
2017
Concise Review: MSC-Derived Exosomes for Cell-Free Therapy.
Stem cells (Dayton, Ohio). 35(4):851-858 [DOI] 10.1002/stem.2575. [PMID] 28294454.
2017
IP6K1 Reduces Mesenchymal Stem/Stromal Cell Fitness and Potentiates High Fat Diet-Induced Skeletal Involution
Stem Cells. 35(8):1973-1983 [DOI] 10.1002/stem.2645. [PMID] 28577302.
2017
Mesenchymal Stem Cells Yield Transient Improvements in Motor Function in an Infant Rhesus Macaque with Severe Early-Onset Krabbe Disease.
Stem cells translational medicine. 6(1):99-109 [DOI] 10.5966/sctm.2015-0317. [PMID] 28170189.
2017
Mesenchymal stromal cells and ischemic heart disease: hitting the target?
Cardiovascular diagnosis and therapy. 7(3):E4-E6 [DOI] 10.21037/cdt.2016.12.04. [PMID] 28567365.
2017
Rapid Generation of miRNA Inhibitor Leads by Bioinformatics and Efficient High-Throughput Screening Methods.
Methods in molecular biology (Clifton, N.J.). 1517:179-198 [PMID] 27924483.
2017
Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit.
Journal of the American Chemical Society. 139(9):3446-3455 [DOI] 10.1021/jacs.6b11273. [PMID] 28240549.
2016
A Clinical Indications Prediction Scale Based on TWIST1 for Human Mesenchymal Stem Cells.
EBioMedicine. 4:62-73 [DOI] 10.1016/j.ebiom.2015.12.020. [PMID] 26981553.
2016
Design of a small molecule against an oncogenic noncoding RNA.
Proceedings of the National Academy of Sciences of the United States of America. 113(21):5898-903 [DOI] 10.1073/pnas.1523975113. [PMID] 27170187.
2016
International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.
Cytotherapy. 18(2):151-9 [DOI] 10.1016/j.jcyt.2015.11.008. [PMID] 26724220.
2016
Isolation of Mouse Bone Marrow Mesenchymal Stem Cells.
Methods in molecular biology (Clifton, N.J.). 1416:205-23 [DOI] 10.1007/978-1-4939-3584-0_11. [PMID] 27236673.
2016
Quantifiable Metrics for Predicting MSC Therapeutic Efficacy.
Journal of stem cell research & therapy. 6(11) [DOI] 10.4172/2157-7633.1000365. [PMID] 28127504.
2016
Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of Osteosarcoma.
Clinical orthopaedics and related research. 474(1):178-89 [PMID] 26463566.
2015
Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs.
Nature communications. 6 [DOI] 10.1038/ncomms9472. [PMID] 26442449.
2015
MSCs: Scientific Support for Multiple Therapies.
Stem cells international. 2015 [DOI] 10.1155/2015/280572. [PMID] 26294916.
2015
Pharmacological repression of PPARγ promotes osteogenesis.
Nature communications. 6 [DOI] 10.1038/ncomms8443. [PMID] 26068133.
2015
Small Molecule Inhibition of miR-544 Biogenesis Disrupts Adaptive Responses to Hypoxia by Modulating ATM-mTOR Signaling.
ACS chemical biology. 10(10):2267-76 [DOI] 10.1021/acschembio.5b00265. [PMID] 26181590.
2014
Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo.
PloS one. 9(1) [DOI] 10.1371/journal.pone.0087238. [PMID] 24489878.
2014
Mesenchymal stem cell biodistribution, migration, and homing in vivo.
Stem cells international. 2014 [DOI] 10.1155/2014/292109. [PMID] 24738002.
2014
Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.
Brain research. 1573:92-107 [DOI] 10.1016/j.brainres.2014.05.029. [PMID] 24858930.
2014
TNFR1/phox interaction and TNFR1 mitochondrial translocation Thwart silica-induced pulmonary fibrosis.
Journal of immunology (Baltimore, Md. : 1950). 192(8):3837-46 [DOI] 10.4049/jimmunol.1103516. [PMID] 24623132.
2013
Mesenchymal stromal cells: misconceptions and evolving concepts.
Cytotherapy. 15(2):140-5 [DOI] 10.1016/j.jcyt.2012.11.005. [PMID] 23321325.
2013
MSCs: science and trials.
Nature medicine. 19(7) [DOI] 10.1038/nm.3220. [PMID] 23836216.
2013
The peculiar biology of mouse mesenchymal stromal cells–oxygen is the key.
Cytotherapy. 15(5):536-41 [DOI] 10.1016/j.jcyt.2012.11.018. [PMID] 23352463.
2012
Atmospheric oxygen inhibits growth and differentiation of marrow-derived mouse mesenchymal stem cells via a p53-dependent mechanism: implications for long-term culture expansion.
Stem cells (Dayton, Ohio). 30(5):975-87 [DOI] 10.1002/stem.1069. [PMID] 22367737.
2012
Functional heterogeneity of mesenchymal stem cells: implications for cell therapy.
Journal of cellular biochemistry. 113(9):2806-12 [DOI] 10.1002/jcb.24166. [PMID] 22511358.
2012
Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells.
Cell stem cell. 10(1):9-10; author reply 10 [DOI] 10.1016/j.stem.2011.12.005. [PMID] 22226349.
2012
MicroRNAs in the imprinted DLK1-DIO3 region repress the epithelial-to-mesenchymal transition by targeting the TWIST1 protein signaling network.
The Journal of biological chemistry. 287(51):42695-707 [DOI] 10.1074/jbc.M112.387761. [PMID] 23105110.
2012
Therapeutic applications of mesenchymal stem cells: current outlook.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 26(4):201-8 [PMID] 22708790.
2011
Clonal analysis of the proliferation potential of human bone marrow mesenchymal stem cells as a function of potency.
Biotechnology and bioengineering. 108(11):2716-26 [DOI] 10.1002/bit.23193. [PMID] 21538337.
2011
Fibroblast growth factor 2 (Fgf2) inhibits differentiation of mesenchymal stem cells by inducing Twist2 and Spry4, blocking extracellular regulated kinase activation, and altering Fgf receptor expression levels.
Stem cells (Dayton, Ohio). 29(7):1102-11 [DOI] 10.1002/stem.661. [PMID] 21608080.
2011
High-capacity assay to quantify the clonal heterogeneity in potency of mesenchymal stem cells.
BMC proceedings. 5 Suppl 8(Suppl 8) [DOI] 10.1186/1753-6561-5-S8-O14. [PMID] 22373225.
2011
Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II.
Stroke. 42(3):825-9 [DOI] 10.1161/STROKEAHA.110.601914. [PMID] 21273569.
2011
Twist, epithelial-to-mesenchymal transition, and stem cells.
Stem cells (Dayton, Ohio). 29(1):3-4 [DOI] 10.1002/stem.553. [PMID] 21280153.
2010
Activation of CD74 inhibits migration of human mesenchymal stem cells.
In vitro cellular & developmental biology. Animal. 46(6):566-72 [DOI] 10.1007/s11626-010-9279-1. [PMID] 20198449.
2010
Cell-dose-dependent increases in circulating levels of immune effector cells in rhesus macaques following intracranial injection of allogeneic MSCs.
Experimental hematology. 38(10):957-967.e1 [DOI] 10.1016/j.exphem.2010.06.011. [PMID] 20600575.
2010
Defining the risks of mesenchymal stromal cell therapy.
Cytotherapy. 12(5):576-8 [DOI] 10.3109/14653249.2010.507330. [PMID] 20735162.
2010
In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment.
Stem cells (Dayton, Ohio). 28(4):788-98 [DOI] 10.1002/stem.312. [PMID] 20127798.
2010
Migratory response of mesenchymal stem cells to macrophage migration inhibitory factor and its antagonist as a function of colony-forming efficiency.
Biotechnology letters. 32(1):19-27 [DOI] 10.1007/s10529-009-0110-6. [PMID] 19705068.
2009
A SAGE View of Mesenchymal Stem Cells.
International journal of stem cells. 2(1):1-10 [PMID] 24855514.
2009
Small-molecule antagonist of macrophage migration inhibitory factor enhances migratory response of mesenchymal stem cells to bronchial epithelial cells.
Tissue engineering. Part A. 15(9):2335-46 [DOI] 10.1089/ten.tea.2008.0434. [PMID] 19260777.
2008
Adipose stromal/stem cells: basic and translational advances: the IFATS collection.
Stem cells (Dayton, Ohio). 26(10):2664-5 [DOI] 10.1634/stemcells.2008-0927. [PMID] 18818434.
2008
Isolation of mesenchymal stem cells from murine bone marrow by immunodepletion.
Methods in molecular biology (Clifton, N.J.). 449:171-86 [DOI] 10.1007/978-1-60327-169-1_12. [PMID] 18370091.
2008
Methods and protocols. Preface.
Methods in molecular biology (Clifton, N.J.). 449:v-vii [PMID] 18453071.
2008
Reprogramming battle: Egg vs. Virus.
Stem cells (Dayton, Ohio). 26(1):1-2 [PMID] 18055442.
2007
Age- and dose-related effects on MSC engraftment levels and anatomical distribution in the central nervous systems of nonhuman primates: identification of novel MSC subpopulations that respond to guidance cues in brain.
Stem cells (Dayton, Ohio). 25(12):3261-70 [PMID] 17932418.
2007
Biochemical heterogeneity of mesenchymal stem cell populations: clues to their therapeutic efficacy.
Cell cycle (Georgetown, Tex.). 6(23):2884-9 [PMID] 18000405.
2007
Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair–current views.
Stem cells (Dayton, Ohio). 25(11):2896-902 [PMID] 17901396.
2007
Cytoplasmic extracts from adipose tissue stromal cells alleviates secondary damage by modulating apoptosis and promotes functional recovery following spinal cord injury.
Brain pathology (Zurich, Switzerland). 17(3):263-75 [PMID] 17465991.
2007
Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells.
Experimental hematology. 35(4):640-52 [PMID] 17379074.
2007
Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury.
Proceedings of the National Academy of Sciences of the United States of America. 104(26):11002-7 [PMID] 17569781.
2006
Biological activities encoded by the murine mesenchymal stem cell transcriptome provide a basis for their developmental potential and broad therapeutic efficacy.
Stem cells (Dayton, Ohio). 24(1):186-98 [PMID] 16100003.
2006
Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis.
Experimental neurology. 198(1):54-64 [PMID] 16336965.
2006
Murine mesenchymal stem cells transplanted to the central nervous system of neonatal versus adult mice exhibit distinct engraftment kinetics and express receptors that guide neuronal cell migration.
Stem cells and development. 15(3):437-47 [PMID] 16846379.
2006
Preclinical evaluation of adult stem cell engraftment and toxicity in the CNS of rhesus macaques.
Molecular therapy : the journal of the American Society of Gene Therapy. 13(6):1173-84 [PMID] 16497561.
2006
Review: ex vivo engineering of living tissues with adult stem cells.
Tissue engineering. 12(11):3007-19 [PMID] 17518617.
2005
Murine mesenchymal and embryonic stem cells express a similar Hox gene profile.
Biochemical and biophysical research communications. 338(4):1759-65 [PMID] 16288716.
2005
Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system.
Current pharmaceutical design. 11(10):1255-65 [PMID] 15853682.
2003
Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection.
Journal of cellular biochemistry. 89(6):1235-49 [PMID] 12898521.
2003
Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects.
Proceedings of the National Academy of Sciences of the United States of America. 100(14):8407-11 [PMID] 12815096.
2003
Quantifying levels of transplanted murine and human mesenchymal stem cells in vivo by real-time PCR.
Cytotherapy. 5(1):7-18 [PMID] 12745583.
2001
MicroSAGE analysis of 2,353 expressed genes in a single cell-derived colony of undifferentiated human mesenchymal stem cells reveals mRNAs of multiple cell lineages.
Stem cells (Dayton, Ohio). 19(5):408-18 [PMID] 11553849.
2000
Pathogenesis of HIV-1 infection within bone marrow cells.
Leukemia & lymphoma. 37(5-6):497-515 [PMID] 11042510.
2000
Potential use of marrow stromal cells as therapeutic vectors for diseases of the central nervous system.
Progress in brain research. 128:293-7 [PMID] 11105688.
2000
Potential use of stem cells from bone marrow to repair the extracellular matrix and the central nervous system.
Biochemical Society transactions. 28(4):341-5 [PMID] 10961915.
1999
Donor variation in the growth properties and osteogenic potential of human marrow stromal cells.
Journal of cellular biochemistry. 75(3):424-36 [PMID] 10536366.
1999
Enhanced in situ detection of beta-glucuronidase activity in murine tissue.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 47(7):965-8 [PMID] 10375385.
1999
Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains.
Proceedings of the National Academy of Sciences of the United States of America. 96(19):10711-6 [PMID] 10485891.
1999
Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: variations in yield, growth, and differentiation.
Journal of cellular biochemistry. 72(4):570-85 [PMID] 10022616.
1999
Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate.
British journal of haematology. 107(2):275-81 [PMID] 10583212.
1998
A 1,064 bp fragment from the promoter region of the Col11a2 gene drives lacZ expression not only in cartilage but also in osteoblasts adjacent to regions undergoing both endochondral and intramembranous ossification in mouse embryos.
Matrix biology : journal of the International Society for Matrix Biology. 17(3):213-21 [PMID] 9707344.
1996
Chromosomal integration dependent induction of junB by growth factors requires multiple flanking evolutionarily conserved sequences.
Oncogene. 13(9):1875-83 [PMID] 8934533.
1995
Analysis of the hormone-dependent regulation of a JunD-estrogen receptor chimera.
The Journal of biological chemistry. 270(19):11502-13 [PMID] 7744790.
1995
Complex genetic organization of junB: multiple blocks of flanking evolutionarily conserved sequence at the murine and human junB loci.
Genomics. 28(2):228-34 [PMID] 8530030.
1994
Quantitative analysis of the contribution made by 5′-flanking and 3′-flanking sequences to the transcriptional regulation of junB by growth factors.
Oncogene. 9(8):2353-62 [PMID] 8036018.

Grants

Mar 2024 ACTIVE
A Clinical Indications Prediction (CLIP) Scale for Human Mesenchymal Stem Cells
Role: Principal Investigator
Funding: NATL INST OF HLTH NHLBI
Sep 2022 ACTIVE
Tissue Selective Glucocorticoids
Role: Co-Investigator
Funding: NATL INST OF HLTH NIGMS
Aug 2022 ACTIVE
A novel miR-544 targeting small molecule as an adjuvant therapy for preventing breast cancer metastasis and relapse
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Apr 2022 – Feb 2024
A Clinical Indications Prediction (CLIP) Scale for Human Mesenchymal Stem Cells
Role: Principal Investigator
Funding: NATL INST OF HLTH NHLBI

Education

Ph.D. in Biochemistry
1990 · Temple University, School of Medicine
Bachelor's of Arts in Chemistry and Mathematics
1984 · The University of Vermont

Contact Details

Phones:
Business:
(561) 228-2214
Emails:
Business:
dphinney@ufl.edu
Manager, Administrative Services:
Addresses:
Business Mailing:
Location A215
130 SCRIPPS WAY BLDG 2A2
JUPITER FL 33458